AU2003287178A1 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
AU2003287178A1
AU2003287178A1 AU2003287178A AU2003287178A AU2003287178A1 AU 2003287178 A1 AU2003287178 A1 AU 2003287178A1 AU 2003287178 A AU2003287178 A AU 2003287178A AU 2003287178 A AU2003287178 A AU 2003287178A AU 2003287178 A1 AU2003287178 A1 AU 2003287178A1
Authority
AU
Australia
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287178A
Other languages
English (en)
Other versions
AU2003287178A8 (en
Inventor
Matthew Lee Brown
Mui Cheung
Scott Howard Dickerson
Cassandra Gauthier
Philip Anthony Harris
Robert Neil Hunter Iii
Gregory Pacofsky
Michael Robert Peel
Jeffrey Alan Stafford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2003287178A1 publication Critical patent/AU2003287178A1/en
Publication of AU2003287178A8 publication Critical patent/AU2003287178A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003287178A 2002-10-10 2003-10-10 Chemical compounds Abandoned AU2003287178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41754802P 2002-10-10 2002-10-10
US60/417,548 2002-10-10
PCT/US2003/033317 WO2004032882A2 (en) 2002-10-10 2003-10-10 Chemical compounds

Publications (2)

Publication Number Publication Date
AU2003287178A1 true AU2003287178A1 (en) 2004-05-04
AU2003287178A8 AU2003287178A8 (en) 2004-05-04

Family

ID=32094036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287178A Abandoned AU2003287178A1 (en) 2002-10-10 2003-10-10 Chemical compounds

Country Status (5)

Country Link
US (1) US7189712B2 (https=)
EP (1) EP1551813A4 (https=)
JP (1) JP2006503081A (https=)
AU (1) AU2003287178A1 (https=)
WO (1) WO2004032882A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
AU2004255934B2 (en) * 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
EP1684750B1 (en) * 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
WO2005102318A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
JP2007538064A (ja) * 2004-05-18 2007-12-27 アブ サイエンス 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
WO2006106437A2 (en) * 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
CN101460470B (zh) 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 作为dgat1抑制剂的1,3,4-二唑衍生物
ES2606505T3 (es) * 2007-01-12 2017-03-24 Ab Science Tratamiento de combinación de cánceres sólidos con antimetabolitos e inhibidores de tirosina quinasa
WO2008128231A1 (en) 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
CN101888999B (zh) * 2007-12-05 2013-12-11 巴斯夫欧洲公司 吡啶基甲基磺酰胺化合物
NZ586104A (en) 2007-12-20 2012-02-24 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
WO2009111502A2 (en) 2008-03-03 2009-09-11 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
TW201103895A (en) 2009-06-19 2011-02-01 Astrazeneca Ab Chemical compounds
US8957216B2 (en) * 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
EP2714667B1 (en) * 2011-05-27 2020-11-25 Laxman S. DESAI Aminooxazole inhibitors of cyclin dependent kinases
CN102757400B (zh) * 2012-07-18 2014-08-06 贵州大学 2,5-取代基噁唑类衍生物及其应用
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
KR101713027B1 (ko) * 2015-12-23 2017-03-07 한국원자력의학원 페닐옥사졸계 유도체를 포함하는 암 예방 또는 치료용 조성물
KR101948555B1 (ko) * 2017-08-03 2019-02-15 한국원자력의학원 수용체 티로신 키나아제 저해제를 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2019164996A1 (en) * 2018-02-21 2019-08-29 Southern Research Institute 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AU2020221370A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid x receptor modulators
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
KR20250144817A (ko) * 2024-03-27 2025-10-13 동국대학교 산학협력단 신규 옥사다이아졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3092946B2 (ja) * 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
BR0116452A (pt) * 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents

Also Published As

Publication number Publication date
EP1551813A2 (en) 2005-07-13
US7189712B2 (en) 2007-03-13
WO2004032882A2 (en) 2004-04-22
WO2004032882A3 (en) 2004-07-08
JP2006503081A (ja) 2006-01-26
EP1551813A4 (en) 2007-07-11
AU2003287178A8 (en) 2004-05-04
US20050288515A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
AU2003287178A1 (en) Chemical compounds
AU2003266949A1 (en) Compounds
AU2003221098A1 (en) Oligofluorenylene compounds
GB0205165D0 (en) Chemical compounds
EG23485A (en) Chemical compounds
GB0203994D0 (en) Chemical compounds
GB0203020D0 (en) Chemical compounds
AU2003290661A1 (en) Chemical compounds
GB0205162D0 (en) Chemical compounds
AU2002366440A1 (en) Chemical compounds
GB0203022D0 (en) Chemical compounds
AU2003284217A1 (en) Chemical compounds
AU2003216859A1 (en) Amidoacetonitrile compounds
GB0205166D0 (en) Chemical compounds
AU2002950405A0 (en) Chemical methods
AU2003292667A1 (en) Benzocycloheptapyridine compounds
AU2003275480A1 (en) Compounds
AU2003255322A1 (en) Compounds
AU2002950917A0 (en) Chemical methods
HK1069387A (en) Chemical compounds
HK1069175A (en) Chemical compounds
HK1086826A (en) Chemical compounds
HK1085475A (en) Chemical compounds
HK1066793A (en) Chemical compounds
HK1067117A (en) Chemical compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase